{
  "abstract": "Background Attachment inhibitor fostemsavir (FTR) and postattachment inhibitor ibalizumab (IBA) are used in people with HIV-1 (PWH) who are highly treatment experienced and harboring multidrug-resistant viruses, and real-world data remain limited. We describe population characteristics and pharmacovirologic outcomes of PWH initiating FTR- or IBA-based regimens. Methods We conducted a French retrospective observational study within the AIDS Research National Agency | Emerging Infectious Diseases virology and pharmacology network. Virologic failure (VF) was defined as 2 consecutive plasma viral loads (VLs) ≥50 copies/mL; nonvirologic response was considered a VL decrease <1 log10 copies/mL or failure to achieve virologic suppression. Results Among 70 PWH receiving FTR-based treatment, 50% were virologically suppressed at initiation; median VL among viremic cases was 3.6 log10 copies/mL. Resistance to at least 2 antiretrovirals was observed among participants by inhibitor class: 96%, nucleoside reverse transcriptase inhibitor; 94%, nonnucleoside reverse transcriptase inhibitor; 74%, protease inhibitor; and 64%, integrase strand transfer inhibitor. The genotypic susceptibility score was ≤1 in 47%, and median follow-up was 20 months. Eight VFs and 8 nonvirologic responses occurred. At failure, emergence of FTR resistance-associated mutations occurred in 1 case. Suboptimal temsavir concentrations were observed in 2 of 8 participants in failure. Eleven PWH who were viremic initiated IBA-based treatment: the genotypic susceptibility score was ≤1 in 4, and median follow-up was 7 months with 5 VFs and 2 nonvirologic responses. One new resistance mutation (N74D, capsid) was detected at VF; suboptimal plasma concentrations of oral antiretrovirals were observed in 3 of 5 participants. Conclusions PWH receiving FTR or IBA had extensive multidrug resistance and limited therapeutic options. Among PWH who were viremic and initiating FTR- and IBA-based regimens, virologic success was achieved in 63% and 36%, respectively, and maintained in 91% who were virologically suppressed and starting an FTR-based regimen.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 50,
  "authors": [
    {
      "name": "Karl Stefic"
    },
    {
      "name": "Camille Tumiotto"
    },
    {
      "name": "Anne de Monte"
    },
    {
      "name": "Marc Wirden"
    },
    {
      "name": "Audrey Rodallec"
    },
    {
      "name": "Djeneba Bocar Fofana"
    },
    {
      "name": "Marie-Laure Chaix"
    },
    {
      "name": "Pantxika Bellecave"
    },
    {
      "name": "Elisabeth André-Garnier"
    },
    {
      "name": "Justine Sourice"
    },
    {
      "name": "Camille Vellas"
    },
    {
      "name": "Stéphanie Raymond"
    },
    {
      "name": "Sidonie Lambert-Niclot"
    },
    {
      "name": "Enagnon Kazali Alidjinou"
    },
    {
      "name": "Pauline Coulon"
    },
    {
      "name": "Véronique Avettand-Fenoel"
    },
    {
      "name": "Gilbert Mchantaf"
    },
    {
      "name": "Lynda Handala"
    },
    {
      "name": "Elodie Alessandri-Gradt"
    },
    {
      "name": "Alice Moisan"
    },
    {
      "name": "Minh Lê"
    },
    {
      "name": "Constance Delaugerre"
    },
    {
      "name": "Anne-Geneviève Marcelin"
    },
    {
      "name": "Gilles Peytavin"
    },
    {
      "name": "Vincent Calvez"
    },
    {
      "name": "Diane Descamps"
    },
    {
      "name": "Charlotte Charpentier"
    },
    {
      "name": "Kevin Alexandre"
    },
    {
      "name": "Clotilde Allavena"
    },
    {
      "name": "Antoine Bachelard"
    },
    {
      "name": "Fabrice Bonnet"
    },
    {
      "name": "Charles Cazanave"
    },
    {
      "name": "David Chirio"
    },
    {
      "name": "Yoann Conan"
    },
    {
      "name": "Eric Cua"
    },
    {
      "name": "Pierre Delobel"
    },
    {
      "name": "Jade Ghosn"
    },
    {
      "name": "Laurent Hocqueloux"
    },
    {
      "name": "Karine Lacombe"
    },
    {
      "name": "Estibalitz Lazaro"
    },
    {
      "name": "Adrien Lemaignen"
    },
    {
      "name": "Guillaume Martin-Blondel"
    },
    {
      "name": "Jean-Michel Molina"
    },
    {
      "name": "Bao Phung"
    },
    {
      "name": "Valérie Pourcher"
    },
    {
      "name": "Caroline Proux"
    },
    {
      "name": "Pascal Pugliese"
    },
    {
      "name": "Mayda Rahi"
    },
    {
      "name": "Christophe Rioux"
    },
    {
      "name": "Olivier Robineau"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/9yp4he2qqra23.bib",
  "cited_by": 0,
  "doi": "10.1093/ofid/ofag495",
  "fulltext_url": null,
  "id": "9yp4he2qqra23",
  "issns": [
    "2328-8957",
    "2328-8957"
  ],
  "landing_url": "https://u-bordeaux.hal.science/hal-05732452v1",
  "language": "en",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.mp"
    ],
    [
      "openalex",
      "2725|HIV/AIDS drug development and treatment"
    ]
  ],
  "openalex": "W7203468659",
  "pdf_url": "https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofag495/70650762/ofag495.pdf",
  "pmcid": null,
  "pmid": "42614621",
  "published": "2026-08-14",
  "publisher": "Oxford University Press",
  "ris": "https://research.draconitic.com/paper/9yp4he2qqra23.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:21Z",
      "native_id": "hal-05732452",
      "source": "hal",
      "url": "https://u-bordeaux.hal.science/hal-05732452v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:1.sdv.mp",
      "subfield": "microbiology"
    }
  ],
  "title": "A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab",
  "title_text": "A French National Real-World Survey of People With Multiresistant HIV-1 Viruses Receiving an Antiretroviral Regimen Including Fostemsavir or Ibalizumab",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:21Z",
  "url": "https://research.draconitic.com/paper/9yp4he2qqra23",
  "venue": "Open Forum Infectious Diseases",
  "versions": []
}